Key facts
- HekaBio’s last known valuation is $100.9M (Jan 2021).
- It has raised $23.7M; the latest was Later Stage VC in Jun 2025.
- Notable investors include Ohara, Alfresa Holdings, Cosmo Public Relations, Essential Pharma (Tokyo), Medifuture — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for HekaBio
- ·The full record, as it builds
Funding rounds
No funding rounds for HekaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HekaBio
Operator of an asset-light healthcare platform intended to offer radiation and other therapies for oncology and fibrotic disease and invest in global healthcare technology. The company offers a broad category of development expertise in pharma, medical devices, in-vitro diagnostics, digital health, and cell and gene therapies, enabling researchers to advance a portfolio of breakthrough programs and provide patients with accelerated access to global healthcare innovations.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2016
- Employees
- 12
- Website
- heka.bio/
- Ownership
- Privately Held (backing)
HekaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HekaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HekaBio in its N-PORT filings yet. We sweep new filings monthly.